nav-left cat-right
cat-right

Rentschler Biotechnologie Announces Cooperation wi...

Laupheim, Germany, Mai 21, 2008 – Rentschler Biotechnologie and Boehringer Ingelheim, both leading companies in biopharmaceutical development and production, have signed a preferred partnership agreement. The cooperation will enable Rentschler Biotechnologie’s clients to gain access to Boehringer Ingelheim’s large-scale mammalian biopharmaceutical production facilities in Biberach, Germany and vice ...

GTCbio’s 3rd Imaging in Pre-clinical & ...

The obstacles to successful drug discovery and development are numerous and well appreciated. In discovery, from target identification through lead optimization and validation, and in development, from first-in-man studies through large registration trials, inefficiencies and uncertainties complicate even well-funded efforts by sophisticated and industrious scientists and clinicians. Despite huge outlays by the worldwide...

Biological Drugs Spurring an Evolution in Injectab...

(Amherst, NH) – The success of recombinant protein drugs such as Enbrel, Remicade, and Herceptin in treating refractory conditions is fueling the search for protein and peptide-based therapeutic agents in oncology, inflammation and a host of other disease classes. Led by the proliferation of antibody-based drug candidates, biological drugs as a class continue to outpace all other NCEs in development pipelines and...

Arena Pharmaceuticals Initiates Second and Third P...

Patients with FDA-defined Valvulopathy Permitted to Enroll in 2nd and 3rd Pivotal Trials – Echocardiogram Screening Requirement Eliminated SAN DIEGO, Dec. 13 /PRNewswire-FirstCall/ — Arena Pharmaceuticals, Inc. today announced the initiation of patient screening in the second and third Phase 3 pivotal trials evaluating the efficacy and safety of its lead drug candidate, lorcaserin hydrochloride, for weight...

7th Annual Protein Kinases Congress 10-12 March 20...

Innovating kinase inhibitor development is the key to successful clinical development. At Informa Life Sciences 7th Annual Protein Kinases Congress hear the latest thinking and strategies towards creating a selective inhibitor. Learn about new targets, industry trends in structure-based drug design, clinical case-studies and discuss the issue of cardiotoxicity. For more information visit:...

New Clinical Trial Code break System ‘Safeco...

‘Safecode’ is a new system for clinical trials represents a significant enhancement over traditional CODEBREAK product identification methods. Our system allows confidential information to be printed using industry standard inkjet technology. The printed information is illegible unless a tamper evident strip is removed. This ensures that any effort to compromise the security of data is immediately...
Page 7 of 8« First...45678